Hi Jr,..I added some more here today. I like the close over $3, as catalysts are getting closer. I can't see any better risk rewards in biotech than IDRA and AVXL. Imo
Thanks for re posting,..great piece of due diligence for new investors here. Just told a few friends and family about AVXL today.
If the market is down a little, neutral, or up- I agree with your assessment. I think we get there this week setting up a nice September.
That's fine. I don't mind your opinion. But, it's this kind of stuff that gives credence to doorknobs coming here and saying pump and dump. AVXL is anything but...I think you've stated your opinion.
Rocket,..you just lost your credibility,..clearly you sold and are nervous about getting back in without paying up. You did the same thing a few weeks ago...
Up for new investors to read,.we are way undervalued here on a good number of accounts...
If you have some free funds,..up 13% despite the overall market performance:
1. Reported preliminary ph 2 AD results that showed treatment to be 4x better than the current standard of care. More data expected in Sept/Oct. this company uses a different mechanism to treat Alzheimer's ( huge market).
2. Received a grant from Michael J Fox foundation last week.
3. Received allowance for Patent last week. Paving way for partnership opportunities.
4. Institutional ownership over 54% per last S1 filing (Sabby, Sphera Global,..)
5. CEO has 4M shares
6. Compare with AXON MC
7. SA author (KKD) thinks it's worth $5 right now as stated on 8/17.
This one is a ground floor opportunity and gaining exposure by the day,..
Give it a check if you have some free funds and doing some bargain hunting,...data on 7/22 showed treatment for Alzheimer's disease (huge market) was 4x better than th current standard of care. Expecting more data in Sept/October. SA author thinks it's worth $5 right now. Up 13% this week,....nice opportunity to keep on your radar.
If any investors here have some free funds and looking for a bargain:
This is what the SA author had to say about AVXL this past week -
I initiated coverage on AVXL almost a month ago. In the article, I had noted that AVXL appears to be the most interesting Alzheimer's disease ("AD") drug company with the lowest valuation. The potential of the company's lead product candidate, Anavex 2-73, was reconfirmed when it released initial data from a Phase 2a study last month. The data showed early evidence of improving condition in patients with AD.
In AD alone, AVXL has a fair value of $5 per share, after adjusting for risk. If you add the potential in Parkinson's, then the potential value of the stock is even higher. If AVXL's concept is proven in AD, it is very likely that it will be proven in Parkinson's as well.